Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GTX Chemotherapy in Carcinoma of Unknown Primary
NCT00119314Phase 2Withdrawn
- Sponsor
- University of Medicine and Dentistry of New Jersey
- Start
- Jul 2004
- Primary completion
- Jul 2005
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, docetaxel, capecitabine in carcinoma of unknown primary (CUP), sponsored by University of Medicine and Dentistry of New Jersey. Planned start Jul 2004; status: withdrawn.
02
Drugs
gemcitabinedocetaxelcapecitabine
03
Conditions
carcinoma of unknown primary (CUP)
Beyond the preview
Go deeper on NCT00119314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00119314.